Toggle Nav
mobile icon
My Cart
Close
  • Menu
  • Setting

Bcr-Abl

Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).

5 Items

per page
  1. Bosutinib (SKI-606)
    A2149 Bosutinib (SKI-606)
     1 Citation
    Target: Bcr-Abl|Src
    Summary: Potent Abl/Src kinases
      ≥26.5 mg/mL
  2. Saracatinib (AZD0530)
    A2133 Saracatinib (AZD0530)
     3 Citation
    Target: Src
    Summary: Src/Abl inhibitor,potent and selective
      ≥27.1 mg/mL
  3. Ponatinib (AP24534)
    A5467 Ponatinib (AP24534)
     1 Citation
    Target: VEGFR|PDGFR|Bcr-Abl|FGFR|Src
    Summary: pan-BCR-ABL inhibitor,multi-kinase inhibitor
      ≥53.3 mg/mL
  4. PD173955
    A8812 PD173955
    Target: Bcr-Abl|Src
    Summary: Dual Src/Abl kinase inhibitor, ATP-competitive,
      ≥22.15 mg/mL
  5. Dasatinib Monohydrate
    B5954 Dasatinib Monohydrate
    Target: PDGFR|c-Kit|Bcr-Abl|Src
    Summary: Inhibitor of ABL, SRC, KIT, PDGFR, and other tyrosine kinases.
      ≥25.3 mg/mL

5 Items

per page
Relate Categories
Now Shopping by
  1. Target Src Remove This Item
Clear All